![]() |
市場調查報告書
商品編碼
2127950
抗菌導管市場:規模、佔有率、成長、全球產業分析、區域趨勢及2026-2034年預測Antimicrobial Catheters Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
2025年全球抗菌導管市場規模為15.3億美元,預計將從2026年的16.4億美元成長至2034年的28億美元,預測期內複合年成長率(CAGR)為6.9%。北美地區在2025年將佔市場主導地位,市場佔有率達37.90%,這主要得益於該地區導管相關感染疾病的高發生率、先進的醫療基礎設施以及對感染預防技術的積極應用。
抗菌導管是一種塗有或浸漬抗菌劑(例如氯己定、銀或抗生素)的特殊醫用導管。其目的是抑制細菌定植,預防導管相關感染,包括導尿管相關尿道感染( CAUTI)和導尿管相關血流感染疾病(CRBSI)。這些導管廣泛應用於醫院、透析中心、加護病房和長期照護機構。
市場概覽
受外科手術量增加、慢性病盛行率上升以及醫院感染預防意識增強的推動,抗菌導管市場正穩定成長。醫療專業人員擴大採用抗菌導管,以減少感染相關併發症、縮短住院時間並改善患者預後。
導管塗層和感染控制解決方案的技術進步正進一步推動市場擴張。各公司正致力於開發抗菌效果較佳、防護時間較長、生物膜形成較少的導管。
主要市場趨勢
抗菌塗層的技術進步
推動市場發展的關鍵趨勢之一是先進抗菌塗層的研發,包括銀基塗層、氯己定-銀-磺胺嘧啶基塗層、含抗生素塗層和不滲漏塗層。這些技術能夠最大限度地減少細菌黏附和生物膜形成,從而增強對透析患者和重症監護室患者等高風險患者的感染預防能力。
2023 年 11 月,CorMedix 的 DefenCath 獲得 FDA 批准,DefenCath 是一種導管封管液,旨在減少使用中央靜脈導管的成年血液透析患者的 CRBSI。
市場促進因素
手術數量增加
一個主要的成長要素是全球手術數量的增加。癌症、心血管疾病和腎臟疾病等慢性疾病增加了對補液、透析和腸外營養的需求,促使中央靜脈導管和尿管的使用量增加。
根據美國癌症協會估計,到 2022 年,全球癌症患者人數約為 2,000 萬,這促使對導管治療和感染預防設備的需求增加。
此外,醫療成本的上升和醫療基礎設施的擴張正在推動抗菌導管的廣泛使用。
市場限制因素
抗菌導管高成本
抗菌導管的高成本仍然是一個重大挑戰,尤其是在新興經濟體。由於預算限制,許多醫療機構仍依賴標準導管,並結合無菌插入技術和感染控制規程。
此外,一些國家有限的保險覆蓋範圍進一步限制了高品質抗菌導管技術的應用。
市場機遇
新興市場醫療設施的擴張
中國、印度和墨西哥等國的醫院、門診手術中心和專科診所的快速擴張,創造了巨大的成長機會。醫療保健支出不斷成長以及手術數量的增加,預計將推動全部區域對抗菌導管的需求。
此外,由於住院時間短、成本低、感染風險小等原因,人們越來越傾向於選擇門診手術中心,這也促進了市場成長。
依產品類型
到 2025 年,由於中央靜脈導管中央靜脈導管相關血流感染 (CLABSI) 的高發病率以及醫院中先進中央靜脈導管的日益普及,中心靜脈導管領域佔了市場主導地位。
預計在預測期內,間歇性導尿管市場將以7.6%的複合年成長率成長。
材料
到 2025 年,矽膠細分市場將佔最大的市場佔有率,達到 37.7%,這得益於住院患者導管使用量的增加以及對耐用且具有生物相容性材料的需求不斷成長。
預計聚氨酯市場將以 7.2% 的複合年成長率成長。
按塗層類型
到 2025 年,銀基材料將以 43.2% 的市場佔有率領先市場,因為它能有效減少生物膜的形成和導管相關感染疾病。
預計抗生素市場將以7.3%的複合年成長率成長。
最終用戶
預計到 2025 年,「醫院和門診手術中心 (ASC)」細分市場將主導市場,到 2026 年,該細分市場預計將佔 69.5% 的市場佔有率,這主要得益於全球外科手術數量的增加和醫院基礎設施的擴張。
區域分析
北美洲
預計到2025年,北美市場規模將達到5.8億美元,並繼續保持其領先區域市場的地位。該地區受惠於高手術量、完善的感染防治措施以及創新導管技術的快速應用。
預計到 2026 年,美國市場規模將達到 5.3 億美元。
歐洲
預計到 2026 年,歐洲市場規模將達到 4.4 億美元,這主要得益於手術數量的增加和先進抗菌設備的廣泛應用。
預計到 2026 年,德國將達到 8,000 萬美元,英國將達到 7,000 萬美元。
亞太地區
預計到 2026 年,亞太地區的市場規模將達到 4.3 億美元,主要得益於醫療保健基礎設施的擴張和對感染控制解決方案日益成長的需求。
預計中國將達到 1.4 億美元,印度將達到 7,000 萬美元,日本將達到 9,000 萬美元。
近期進展包括新型抗菌中央靜脈導管、獲得 FDA 批准、建立策略合作夥伴關係以及擴大感染預防研究舉措。
The global antimicrobial catheters market was valued at USD 1.53 billion in 2025 and is projected to grow from USD 1.64 billion in 2026 to USD 2.80 billion by 2034, registering a CAGR of 6.9% during the forecast period. North America dominated the market with a 37.90% share in 2025, supported by a high prevalence of catheter-associated infections, advanced healthcare infrastructure, and strong adoption of infection-prevention technologies.
Antimicrobial catheters are specialized medical tubes coated or infused with antimicrobial agents such as chlorhexidine, silver, and antibiotics to reduce bacterial colonization and prevent catheter-associated infections, including Catheter-Associated Urinary Tract Infections (CAUTIs) and Catheter-Related Bloodstream Infections (CRBSIs). These devices are widely used in hospitals, dialysis centers, intensive care units, and long-term care settings.
Market Overview
The market is experiencing steady growth due to increasing surgical procedures, rising chronic disease prevalence, and growing awareness regarding hospital-acquired infection prevention. Healthcare providers are increasingly adopting antimicrobial catheters to reduce infection-related complications, shorten hospital stays, and improve patient outcomes.
Technological advancements in catheter coatings and infection-control solutions are further driving market expansion. Companies are focusing on developing catheters with enhanced antimicrobial efficacy, longer-lasting protection, and reduced biofilm formation.
Key Market Trend
Technological Advancements in Antimicrobial Coatings
A major trend shaping the market is the development of advanced antimicrobial coatings, including silver-based, chlorhexidine-silver sulfadiazine, antibiotic-infused, and non-leaching coatings. These technologies help minimize bacterial adhesion and biofilm formation, offering better protection against infections in high-risk patients such as dialysis users and ICU patients.
In November 2023, CorMedix Inc. received FDA approval for DefenCath, a catheter lock solution designed to reduce CRBSIs in adult hemodialysis patients using central venous catheters.
Market Drivers
Increasing Number of Surgical Procedures
The rising volume of surgical procedures worldwide is a major growth driver. Chronic diseases such as cancer, cardiovascular disorders, and kidney disease are increasing the demand for fluid administration, dialysis, and parenteral nutrition, thereby boosting the use of central venous and urinary catheters.
According to the American Cancer Society, approximately 20 million cancer cases were estimated globally in 2022, contributing to higher demand for catheter-based therapies and infection-prevention devices.
Additionally, growing healthcare expenditure and expansion of healthcare infrastructure are supporting wider adoption of antimicrobial catheters.
Market Restraints
High Cost of Antimicrobial Catheters
The high cost of antimicrobial catheters remains a significant challenge, particularly in emerging economies. Many healthcare facilities continue to rely on standard catheters combined with sterile insertion techniques and infection-control protocols due to budget limitations.
Limited reimbursement policies in several countries further restrict the adoption of premium antimicrobial catheter technologies.
Market Opportunities
Expansion of Healthcare Facilities in Emerging Markets
Rapid expansion of hospitals, ambulatory surgical centers, and specialty clinics in countries such as China, India, and Mexico is creating substantial growth opportunities. Increasing healthcare spending and rising surgical volumes are expected to drive demand for antimicrobial catheters across these regions.
The growing preference for ambulatory surgical centers due to shorter stays, lower costs, and reduced infection risks is also supporting market growth.
By Product Type
The central venous catheters segment dominated the market in 2025 due to the high incidence of Central Line-Associated Bloodstream Infections (CLABSIs) and increasing use of advanced central venous catheters in hospitals.
The intermittent catheters segment is expected to grow at a CAGR of 7.6% during the forecast period.
By Material
The silicone segment held the largest share at 37.7% in 2025, supported by rising catheter usage in hospitalized patients and increasing demand for durable, biocompatible materials.
The polyurethane segment is projected to grow at 7.2% CAGR.
By Coating Type
The silver-based segment led the market with a 43.2% share in 2025, driven by its effectiveness in reducing biofilm formation and catheter-associated infections.
The antibiotic-based segment is expected to grow at 7.3% CAGR.
By End User
The hospitals & ASCs segment dominated the market in 2025 and is projected to hold 69.5% of the market in 2026, supported by increasing surgical procedures and growing hospital infrastructure worldwide.
Regional Analysis
North America
North America generated USD 0.58 billion in 2025 and remained the leading regional market. The region benefits from high surgical volumes, strong infection-prevention programs, and rapid adoption of innovative catheter technologies.
The U.S. market is projected to reach USD 0.53 billion in 2026.
Europe
Europe is expected to reach USD 0.44 billion in 2026, driven by increasing surgical procedures and growing adoption of advanced antimicrobial devices.
Germany is projected to reach USD 0.08 billion and the U.K. USD 0.07 billion in 2026.
Asia Pacific
Asia Pacific is projected to reach USD 0.43 billion in 2026, supported by expanding healthcare infrastructure and rising demand for infection-control solutions.
China is expected to generate USD 0.14 billion, while India and Japan are projected to reach USD 0.07 billion and USD 0.09 billion, respectively.
Competitive Landscape
The market is moderately consolidated, with major players focusing on product innovation, clinical studies, partnerships, and acquisitions.
Key companies include:
Recent developments include new antimicrobial central venous catheters, FDA approvals, strategic partnerships, and expansion of infection-prevention research initiatives.
Conclusion
The antimicrobial catheters market is expected to grow from USD 1.53 billion in 2025 to USD 2.80 billion by 2034, driven by rising catheter-associated infections, increasing surgical procedures, and continuous technological innovation. While high device costs remain a challenge, expanding healthcare infrastructure, growing awareness of infection prevention, and the introduction of advanced antimicrobial coatings are expected to create strong long-term growth opportunities. North America currently leads the market, while Asia Pacific is emerging as a rapidly growing region for future expansion.
Segmentation By Product Type, Material, Coating Type, End User, and Region
By Product Type * Central Venous Catheters
By Material * Silicone
By Coating Type * Silver-based
By End User * Hospitals & ASCs
By Region * North America (By Product Type, By Material, By Coating Type, By End User, and by Country)